Skip to content

Amgen Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 3, 2026 results vs estimates

Amgen Inc · E.AMGN.NASDAQ · United States
Use symbol E.AMGN.NASDAQ in our API & Excel add-in to retrieve this data ↓
460.73
(+0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 25.41%

Amgen Inc Forecast

Amgen Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 25.4% a year, a typical one-standard-deviation range is 444.24–477.22 over a week, 426.93–494.53 over a month and 343.64–577.82 over a year. (Signals as of 1 Nov 2026.)

Amgen Inc Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Amgen Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Amgen Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Amgen Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Amgen Inc
P/E
26.79x
Mid-range vs own history
QoQ −2.0%
YoY +2.6%
now 26.787222.76 low29.74 high
ⓘP/E As of 22 Nov 2026.See Amgen Inc returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Amgen Inc
P/S
6.47x
Stretched vs own history
QoQ +3.1%
YoY +27.1%
now 6.46634.77 low6.65 high
ⓘP/S As of 22 Nov 2026.See Amgen Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Amgen Inc
P/B
17.53x
Cheap vs own history
QoQ −14.3%
YoY −7.8%
now 17.527816.57 low24.34 high
ⓘP/B As of 22 Nov 2026.See Amgen Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Amgen Inc
EV/EBITDA
16.09x
Stretched vs own history
QoQ +0.4%
YoY +16.7%
now 16.091113.14 low16.84 high
ⓘEV/EBITDA As of 22 Nov 2026.See Amgen Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Amgen Inc
EV/Sales
7.52x
Stretched vs own history
QoQ +1.4%
YoY +18.5%
now 7.51555.99 low7.79 high
ⓘEV/Sales As of 22 Nov 2026.See Amgen Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Amgen Inc
FCF Yield
3.8%
Weak vs own history
QoQ −10.5%
YoY −39.6%
now 3.80873.77 low6.7 high
ⓘFCF Yield As of 22 Nov 2026.See Amgen Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Amgen Inc
Earnings Yield
3.7%
Mid-range vs own history
QoQ +2.0%
YoY −2.5%
now 3.73313.36 low4.39 high
ⓘEarnings Yield As of 22 Nov 2026.See Amgen Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Amgen Inc
Dividend Yield
2.1%
Weak vs own history
QoQ −3.5%
YoY −22.7%
now 2.13312.08 low2.93 high
ⓘDividend Yield As of 22 Nov 2026.See Amgen Inc returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Amgen Inc
Market Cap
$251.6B
Highest in 5 years
QoQ +5.3%
YoY +37.5%
now 251558.58172,215 low254,256 high
ⓘMarket Cap As of 22 Nov 2026.See Amgen Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Amgen Inc
Net Debt
$40.8B
Mid-range vs own history
QoQ −5.8%
YoY −9.6%
now 4081740,817 low45,475 high
ⓘNet Debt As of 22 Nov 2026.See Amgen Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Amgen Inc
Net Debt / EBITDA
2.25x
Mid-range vs own history
QoQ −8.6%
YoY −17.7%
now 2.24642.25 low2.73 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Amgen Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Amgen Inc
Current Ratio
1.48x
Mid-range vs own history
QoQ +7.9%
YoY +15.6%
now 1.47921.14 low1.48 high
ⓘCurrent Ratio As of 22 Nov 2026.See Amgen Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Amgen Inc
Quick Ratio
1.20x
Mid-range vs own history
QoQ +6.8%
YoY +21.8%
now 1.20420.9 low1.2 high
ⓘQuick Ratio As of 22 Nov 2026.See Amgen Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Amgen Inc
Interest Coverage
5.19x
Mid-range vs own history
QoQ +6.9%
YoY +33.8%
now 5.19273.88 low5.19 high
ⓘInterest Coverage As of 22 Nov 2026.See Amgen Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Amgen Inc
Debt / Equity
3.76x
Low vs own history
QoQ −23.2%
YoY −33.7%
now 3.7633.76 low6.31 high
ⓘDebt / Equity As of 22 Nov 2026.See Amgen Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Amgen Inc
Piotroski F-Score
8
Mid-range vs own history
QoQ 0.0%
YoY 0.0%
now 87 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Amgen Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Amgen Inc
Altman Z-Score
2.57
Strong vs own history
QoQ +9.7%
YoY +36.9%
now 2.57321.8 low2.59 high
ⓘAltman Z-Score As of 22 Nov 2026.See Amgen Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Amgen Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Amgen Inc fundamentals: income statement, balance sheet & cash flow

Amgen Inc reported revenue of $36.74bn and net income of $7.71bn in FY2025, the year ended 31 December 2025 — revenue up 9.9% and net income up 88.5% on the prior year. Free cash flow was $8.10bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$36.74bn
+9.9%
Net income
$7.71bn
+88.5%
Gross margin
70.80%
Free cash flow
$8.10bn
-22.1%
Net debt
$45.48bn
Shares short (30 Oct 2026)
12.59m
4.97 days to cover
Amgen Inc income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue36.7433.4228.1926.3225.98
Cost of revenue10.7312.868.456.416.45
Gross profit26.0120.5719.7419.9219.53
Research & development6.975.964.784.436.32
Operating income9.087.267.909.577.64
EBITDA16.9013.367.9012.1711.30
Interest expense2.763.162.881.411.20
Pre-tax income8.984.617.867.356.70
Income tax1.270.521.140.790.81
Net income7.714.096.726.555.89

Download Amgen Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.AMGN.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 41 fiscal years and 165 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Amgen Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Amgen Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Amgen Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

About Amgen Inc (United States)

Amgen Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Amgen Inc

Frequently asked questions

What is Amgen Inc?
Amgen Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the trading strategies that hold it and free historical data.
What is the latest Amgen Inc price?
The latest close is 460.73 (1 Nov 2026), +0.02% on the day. The price at the top of the page refreshes during the trading day.
Is Amgen Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Amgen Inc?
20-day realised volatility is 25.4% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 7.3% over a month and 3.6% over a week.
What factors affect Amgen Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Amgen Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Amgen Inc?
58 backtested tactical asset allocation strategies trade Amgen Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
Where can I download free Amgen Inc historical data?
In the Free historical data section of this page: the last 10 years of Amgen Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Amgen Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Amgen Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.AMGN.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20435.64
2026-11-19436.3
2026-11-18441.341
2026-11-17455.3
2026-11-16459.665
2026-11-13462.996
2026-11-12464.378
2026-11-11465.422
2026-11-10462.558
2026-11-09462.558
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he